Intellia Therapeutics (NASDAQ:NTLA) Given New $15.00 Price Target at Wells Fargo & Company

Intellia Therapeutics (NASDAQ:NTLA) had its target price lifted by Wells Fargo & Company from $12.00 to $15.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other research analysts have also weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Barclays lowered their price target on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, November 7th. KeyCorp set a $25.00 price objective on Intellia Therapeutics in a research report on Wednesday, January 28th. Finally, William Blair raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Ten equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.14.

Intellia Therapeutics Trading Down 11.9%

Intellia Therapeutics stock opened at $13.60 on Tuesday. The company has a 50-day moving average price of $12.09 and a 200 day moving average price of $13.10. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25. The stock has a market cap of $1.61 billion, a P/E ratio of -3.55 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. During the same period in the previous year, the business posted ($1.27) EPS. Intellia Therapeutics’s revenue was up 78.4% on a year-over-year basis. As a group, analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Buying and Selling

In related news, EVP James Basta sold 10,397 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,051 shares of company stock valued at $488,600 in the last ninety days. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $245,000. Invesco Ltd. boosted its stake in shares of Intellia Therapeutics by 5.8% in the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after buying an additional 23,870 shares during the period. Axxcess Wealth Management LLC grew its position in shares of Intellia Therapeutics by 20.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock worth $192,000 after buying an additional 3,583 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $90,000. Finally, XTX Topco Ltd purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $402,000. 88.77% of the stock is owned by institutional investors and hedge funds.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.